Floorstocks Releases Exclusive Nasdaq MarketSite Interview with Wellgistics Health Inc. (NASDAQ: WGRX)
Watch the full interview on YouTube:
https://youtu.be/gJJlbqd7Mv8
Also streaming at Floorstocks.com:
https://www.floorstocks.com
Hosted by market veteran Kenneth Polcari, the interview unpacks how Wellgistics is modernizing the $600+ billion U.S. prescription drug market—eliminating intermediaries, restoring transparency, and enabling faster, compliant fulfillment from manufacturer to patient.
'This is the kind of story our audience responds to—real revenue, strong leadership, and a disruptive path forward,' said Richard Davis, CEO of Floorstocks. 'The Wellgistics message is timely, clear, and rooted in solving systemic inefficiencies that the market can no longer ignore.'
The conversation highlights Wellgistics' vertically integrated tech stack, growing national footprint, and its AI-powered infrastructure supporting pharmacies, providers, manufacturers, and employer groups.
'We appreciated the opportunity to speak directly to the investor community through Floorstocks,' said Brian Norton, CEO of Wellgistics Health. 'They have our full permission to distribute, quote, and promote this interview. We believe transparency builds trust—and this conversation lays out our vision clearly: fixing a broken system with scalable solutions built for today's healthcare challenges.'
This feature is part of a larger investor education campaign aimed at bringing institutional visibility to Wellgistics Health as it scales its direct distribution network, expands employer carve-out programs, and doubles down on compliant, tech-enabled pharmacy solutions.
About Floorstocks
Floorstocks is a financial media platform connecting high-growth public companies with the next generation of investors. Through exclusive interviews, omnichannel storytelling, and high-impact distribution across YouTube, X (Twitter), Instagram, TikTok, and email, Floorstocks is redefining how public markets are explained to the modern investor. Learn more at www.floorstocks.com.
About Wellgistics Health Inc (NASDAQ: WGRX)
Wellgistics Health moves medications from maker to taker—faster, cheaper, and smarter. Its platform spans wholesale distribution, digital script routing, and hub services like eligibility, prior authorization, adherence, and direct-to-patient fulfillment. A PBM alternative—but PBM-agnostic—WGRX empowers manufacturers, providers, pharmacies, and employer groups with transparent, end-to-end medication access.
Media ContactRichard DavisChief Executive Officer, Floorstocks
[email protected] (212) 555-0192
www.floorstocks.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 minutes ago
- Business Wire
Casey's Announces Timing of First Quarter Earnings Release and Conference Call
ANKENY, Iowa--(BUSINESS WIRE)--Casey's General Stores, Inc. ('Casey's' or the 'Company') (Nasdaq: CASY), one of the leading convenience store chains in the United States, will issue first quarter fiscal 2026 results after the market closes on September 8 th, 2025. Casey's will hold a conference call and webcast on Tuesday, September 9 th at 7:30am central to review the results. A live webcast of the event will be available on Casey's website on the Investor Relations page at For those unable to listen to the live broadcast, an audio replay will be available on Casey's for twelve months. Casey's is a Fortune 500 company (Nasdaq: CASY) operating approximately 2,900 convenience stores. Founded more than 50 years ago, the company has grown to become the third-largest convenience store retailer and the fifth-largest pizza chain in the United States. Casey's provides freshly prepared foods, quality fuel and friendly service at its locations. Guests can enjoy pizza, donuts, other assorted bakery items, and a wide selection of beverages and snacks. Learn more and order online at or in the mobile app. CASY-IR
Business Wire
11 minutes ago
- Business Wire
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ('Unicycive' or 'the Company') (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 29, 2024 and June 27, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before October 14, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Unicycive overstated its ability to satisfy FDA manufacturing compliance requirements. The Company overstated the chances of FDA approval for OLC, its treatment for hyperphosphatemia in CKD patients on dialysis. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Unicycive, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
29 minutes ago
- Yahoo
Marvell Technology (MRVL) Stock Gains 10% as Microsoft AI Chip Potential Sparks Interest
Marvell Technology, Inc. (NASDAQ:MRVL) is one of the top stocks sold by hedge funds. On July 30, MRVL stock rose 10% following Fubon Research's emphasis on the company's strong revenue potential tied to Microsoft's AI chip developments. Fubon Research says Microsoft has upgraded the Maia300 chip, which Marvell is working on, from 3nm with HBM3E to a newer 2nm design with HBM4. This change has pushed production from early 2026 to late 2026, but analysts still see it as a big opportunity for Marvell. Copyright: ralwel / 123RF Stock Photo The Maia300 chip is set to start production in late 2026 with about 300,000 to 400,000 units, increasing to 1.2 to 1.5 million units in 2027. At an average price of $8,000 per chip, Fubon expects the project could bring in around $2.4 billion in 2026 and $10 to $12 billion in 2027. Analysts noted that Microsoft seems to have more confidence in Marvell's Maia300 than in its own Maia200 chip. This change comes as Microsoft is reportedly struggling with its in-house chip design, and Fubon believes the company will likely rely more on Marvell for its current chips. The research also pointed out that Microsoft has increased the 2026 production of its Maia200 chip from 40,000-60,000 units to 150,000-200,000 units to make up for the delayed launch of the Maia300. Fubon's report added that Microsoft might charge more than Amazon Web Services (AWS), as the Maia300 has an average price of $8,000, much higher than AWS Trainium 2's $1,500, even though both have similar margins of 55-60%. Marvell Technology, Inc. (NASDAQ:MRVL) delivers comprehensive semiconductor solutions across the data infrastructure spectrum, with a portfolio including system-on-a-chip architectures, Ethernet solutions, storage controllers, interconnect products, and different host system interfaces. While we acknowledge the potential of MRVL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
